Tecentriq – eBook Display Banners Conference – 54259

Disease-free survival could be predicted by high expression of TGFβ CAF in patients with eNSCLC treated with atezolizumab.

Although immunotherapy advances have improved cancer treatments, there remains a need for reliable biomarkers.

“With lung cancer we’re treating more patients effectively today and even curing them because we’re using our most effective therapies earlier.”

Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.

For a retrospective study involving 607 oncology patients treated from 2014-2019, the potential for predicting patient prognosis and guiding immunotherapy treatment through the analysis of total tumor volume (TTV) and artificial intelligence (AI) tumor heterogeneity from CT scans was investigated.

In early-stage non-small cell lung cancer (NSCLC), the recommended treatment options include targeted and immune therapies.

In the management of early-stage non-small cell lung cancer (eNSCLC), the introduction of PD-1/PD-L1 checkpoint inhibitors has marked a significant advancement.

Cancer-associated fibroblasts (CAFs) constitute a critical element of the tumor microenvironment, and TGFβ-induced CAFs have been implicated in poor prognosis across various indications.

One of ESMO’s most popular track is its Young Oncologist Track designed and initiated by the ESMO Young Oncologist Committee.

There are more than 50 satellite symposia sessions taking place at ESMO. Follow PW for conference coverage.

Take a look at ESMO’s keynote sessions and full schedule. Follow PW for conference coverage.